BIOMAT Database Logo BIOMAT Database Logo

Multilineage cell involvement in Ph1-negative, bcr-negative chronic myeloid leukemia. 1988

V Callea, and F Morabito, and P Lista, and L Pegoraro, and G R Cambrin, and A Guerrasio, and G Saglio, and A Tassinari, and M T Fierro, and P Iacopino
Divisione di Ematologia, Ospedali Riuniti di Reggio Calabria, Torino, Italy.

We report a case of Ph1-negative, bcr-negative CML-BC, in which the primary leukemic cells displayed T-related antigens (CD7, CD4) in addition to HLA-DR and CD25 determinants. No B-lymphoid, myeloid and megakaryoblastic surface antigens were detected. In spite of this phenotype, DNA analysis revealed a germ-line configuration of the T-cell receptor beta chain gene region. Moreover, in-vitro culture studies demonstrated a proliferative response of the blast cell population to natural and recombinant myeloid-related factors, while no proliferative signal was observed in the presence of IL-2. The myeloid lineage was further demonstrated by the expression of myeloid-associated antigens on cultured blast cells, which still retained the CD7 antigen. Finally, cytogenetic analysis revealed a monosomy 7 which is usually associated with a stem cell leukemia. These results support the hypothesis that Ph1-negative, bcr-negative CML is characterized by the involvement of a multipotent stem cell capable of multilineage expression and indicate that differentiative and proliferative assays provide a further tool towards a more precise recognition of hematological disorders of uncertain origin.

UI MeSH Term Description Entries
D008297 Male Males
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D002869 Chromosome Aberrations Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS. Autosome Abnormalities,Cytogenetic Aberrations,Abnormalities, Autosome,Abnormalities, Chromosomal,Abnormalities, Chromosome,Chromosomal Aberrations,Chromosome Abnormalities,Cytogenetic Abnormalities,Aberration, Chromosomal,Aberration, Chromosome,Aberration, Cytogenetic,Aberrations, Chromosomal,Aberrations, Chromosome,Aberrations, Cytogenetic,Abnormalities, Cytogenetic,Abnormality, Autosome,Abnormality, Chromosomal,Abnormality, Chromosome,Abnormality, Cytogenetic,Autosome Abnormality,Chromosomal Aberration,Chromosomal Abnormalities,Chromosomal Abnormality,Chromosome Aberration,Chromosome Abnormality,Cytogenetic Aberration,Cytogenetic Abnormality
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000945 Antigens, Differentiation, T-Lymphocyte Antigens expressed on the cell membrane of T-lymphocytes during differentiation, activation, and normal and neoplastic transformation. Their phenotypic characterization is important in differential diagnosis and studies of thymic ontogeny and T-cell function. Antigens, Differentiation, T-Cell,Differentiation Antigens, T-Cell,L3T4 Antigens,Leu Antigens, T-Lymphocyte,T-Cell Differentiation Antigens,T-Lymphocyte Differentiation Antigens,T6 Antigens,Antigens, Differentiation, T Lymphocyte,Differentiation Antigens, T Lymphocyte,Antigens, L3T4,Antigens, T-Cell Differentiation,Antigens, T-Lymphocyte Differentiation,Antigens, T-Lymphocyte Leu,Antigens, T6,Differentiation Antigens, T Cell,Differentiation Antigens, T-Lymphocyte,Leu Antigens, T Lymphocyte,T Cell Differentiation Antigens,T Lymphocyte Differentiation Antigens,T-Lymphocyte Leu Antigens
D013936 Thymidine A nucleoside in which THYMINE is linked to DEOXYRIBOSE. 2'-Deoxythymidine,Deoxythymidine,2' Deoxythymidine
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D014410 Tumor Stem Cell Assay A cytologic technique for measuring the functional capacity of tumor stem cells by assaying their activity. It is used primarily for the in vitro testing of antineoplastic agents. Clonogenic Cell Assay, Tumor,Colony-Forming Units Assay, Tumor,Neoplasm Stem Cell Assay,Stem Cell Assay, Tumor,Colony Forming Units Assay, Tumor

Related Publications

V Callea, and F Morabito, and P Lista, and L Pegoraro, and G R Cambrin, and A Guerrasio, and G Saglio, and A Tassinari, and M T Fierro, and P Iacopino
[Does Ph1-negative chronic myeloid leukemia exist?].
November 1986, Medicina clinica,
V Callea, and F Morabito, and P Lista, and L Pegoraro, and G R Cambrin, and A Guerrasio, and G Saglio, and A Tassinari, and M T Fierro, and P Iacopino
BCR-ABL-negative chronic myeloid leukemia.
May 2007, Current hematologic malignancy reports,
V Callea, and F Morabito, and P Lista, and L Pegoraro, and G R Cambrin, and A Guerrasio, and G Saglio, and A Tassinari, and M T Fierro, and P Iacopino
Involvement of the p53 tumor suppressor gene in Ph1-positive and Ph1-negative myeloid leukemia.
November 1990, Blood,
V Callea, and F Morabito, and P Lista, and L Pegoraro, and G R Cambrin, and A Guerrasio, and G Saglio, and A Tassinari, and M T Fierro, and P Iacopino
Philadelphia (Ph1)-negative myeloid/natural killer cell precursor leukemia evolving during Ph1-positive chronic myelogenous leukemia: report of two cases.
December 2004, Leukemia,
V Callea, and F Morabito, and P Lista, and L Pegoraro, and G R Cambrin, and A Guerrasio, and G Saglio, and A Tassinari, and M T Fierro, and P Iacopino
[bcr rearrangement in variant Ph1-positive chronic myelocytic leukemia].
August 1988, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,
V Callea, and F Morabito, and P Lista, and L Pegoraro, and G R Cambrin, and A Guerrasio, and G Saglio, and A Tassinari, and M T Fierro, and P Iacopino
Variant ph1 translocation in chronic myeloid leukemia.
July 1979, Blood,
V Callea, and F Morabito, and P Lista, and L Pegoraro, and G R Cambrin, and A Guerrasio, and G Saglio, and A Tassinari, and M T Fierro, and P Iacopino
Missing Y chromosome in Ph1-negative chronic myeloid leukemia with bcr rearrangement. Evidence for a bcr-abl recombination on chromosome 22 by in situ hybridization.
January 1991, Acta haematologica,
V Callea, and F Morabito, and P Lista, and L Pegoraro, and G R Cambrin, and A Guerrasio, and G Saglio, and A Tassinari, and M T Fierro, and P Iacopino
Letter: Philadelphia chromosome (Ph1) translocation in an apparently Ph1 negative, minus G22, case of chronic myeloid leukemia.
July 1974, The New England journal of medicine,
V Callea, and F Morabito, and P Lista, and L Pegoraro, and G R Cambrin, and A Guerrasio, and G Saglio, and A Tassinari, and M T Fierro, and P Iacopino
The bcr gene is joined to c-abl in Ph1 chromosome negative chronic myelogenous leukemia.
January 1988, Oncogene research,
V Callea, and F Morabito, and P Lista, and L Pegoraro, and G R Cambrin, and A Guerrasio, and G Saglio, and A Tassinari, and M T Fierro, and P Iacopino
Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia.
January 2021, Frontiers in oncology,
Copied contents to your clipboard!